BioVie CEO on Parkinson's, Long COVID Trials & DNA Age Reversal

BioVie's Clinical Trials Update

• 🚀 BioVie is currently conducting two pivotal clinical trials: one for Parkinson's disease and another for long COVID.
• 💡 The Parkinson's trial aims to establish Bascistirum as a potential first-line monotherapy, a significant development if successful, as it could be the first new Parkinson's therapy in over 50 years.
• 🎯 The long COVID trial explores Bascistirum's potential to alleviate symptoms like brain fog, malaise, and fatigue affecting millions.
• 🗓️ Top-line data for both trials is anticipated in the first half of 2026.

Bascistirum and DNA Methylation Insights

• 🧬 DNA methylation is a natural aging process where methyl groups accumulate on DNA, akin to fingerprints on a DVD, potentially hindering DNA decoding and contributing to age-related diseases.
• 📈 Preliminary data presented shows patients treated with Bascistirum for six months experienced up to a five-year advantage on biological clocks, indicating a deceleration in DNA methylation.
• ⚠️ While not reversing aging itself, this suggests Bascistirum may help individuals stay healthier for longer by reducing DNA methylation.

Gene Modulation and Inflammation Reduction

• 🔬 Further analysis revealed that Bascistirum modulates the expression of dozens of genes in the inflammatory cascade, reducing inflammatory cytokines like TNF alpha and interleukins.
• 🧠 The compound also showed beneficial modulation of genes associated with aging and Alzheimer's pathology, as identified by the National Institute on Aging.
• 📊 Additionally, Bascistirum appeared to modulate genes related to carbohydrate metabolism, glycolysis, and type 2 diabetes, suggesting a broad mechanism of action focused on reducing inflammation.

Corporate Developments and Advisory Board

• 🧑‍💼 BioVie has appointed two new board members: Dr. Amy Chapel, with extensive CNS drug approval experience, and Camille Fariq, bringing valuable finance and capital markets expertise.
• 🤝 A unique Corporate Advisory Board has been formed, comprising leaders from diverse backgrounds, including Ugochi Owo, CEO of Flindel, who highlighted the mission-driven culture and the personal impact of neurological diseases on board members.
• 🗣️ The advisory board aims to raise awareness for conditions like dementia, Parkinson's, and Alzheimer's, emphasizing that patients and families are not alone and that solutions are actively being developed.

BioVie's Strategic Focus

• 🎯 BioVie's primary focus is the execution of its clinical trials to demonstrate Bascistirum's full potential.
• 📢 A key secondary focus is increasing awareness of the company's innovative approach and unique product portfolio.
• 🌟 The ultimate goal is to prepare for the top-line data readout in 2026, aiming to bring new solutions for devastating diseases.